AIDS immune purifier

Abstract

An AIDS immune purifier used in the medical field is characterized in that a separator capable of separating hemocyte from plasma is manufactured, HIVgp120 and gp41 antibodies are prepared and combined with HIVgp120 and gp41 antibodies of anti-goat Ig, a CD4+T cell line is constructed through foreign gene transfection, a specific molecular antibody on the surface of the CD4+T cell line serves as a growth stimulant for amplification, the preparations are mixed with agar gel, the mixture is wrapped by a high-biocompatibility material to form the purifier, the gel is distributed in layers from top to bottom with antibody titer gradually reduced and the agarose concentration gradually increased, and the gp120 and gp41 antibodies combined with anti-goat Ig and not combined with anti-goat Ig and the CD4+T cell line are fixed in the agar gel to achieve the HIV adsorption function; the manufactured purifier is combined with the separator and a control program in use, blood in extracorporeal circulation is separated into plasma and hemocyte by the separator, the plasma is combined with the hemocyte after HIV is filtered away by the purifier, and then blood is transfused back.

Description

technical field [0001] The invention relates to the preparation and application of an AIDS immune purifier in the medical field, which is mainly used for the elimination of plasma HIV in AIDS patients so as to achieve the purpose of treating AIDS. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tuberculosis, and diabetes, and has become a serious public health and s...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, it will produce an immune effect, or it will mediate the ADCC effect to dissolve the cellular antigen by activating complement, but HIV does not Cellular antigens; either attract phagocytes to engulf antigens through chemotaxis, but HIV is protected and proliferated in phagocytes instead; or antibodies combine with antigens to neutralize and make them lose their infectivity, but the structure of HIV antigens is variable, often make it difficult for antibodies to recognize

[0005] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity,

Images